218 related articles for article (PubMed ID: 11327199)
1. Delavirdine: clinical pharmacokinetics and drug interactions.
Tran JQ; Gerber JG; Kerr BM
Clin Pharmacokinet; 2001; 40(3):207-26. PubMed ID: 11327199
[TBL] [Abstract][Full Text] [Related]
2. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Barry M; Mulcahy F; Merry C; Gibbons S; Back D
Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
Ferry JJ; Herman BD; Carel BJ; Carlson GF; Batts DH
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):252-9. PubMed ID: 9665503
[TBL] [Abstract][Full Text] [Related]
6. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Wire MB; Shelton MJ; Studenberg S
Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
Smith PF; DiCenzo R; Morse GD
Clin Pharmacokinet; 2001; 40(12):893-905. PubMed ID: 11735608
[TBL] [Abstract][Full Text] [Related]
8. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Fletcher CV; Acosta EP; Cheng H; Haubrich R; Fischl M; Raasch R; Mills C; Hu XJ; Katzenstein D; Remmel RP; Gulick RM;
AIDS; 2000 Nov; 14(16):2495-501. PubMed ID: 11101060
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
Borin MT; Chambers JH; Carel BJ; Freimuth WW; Aksentijevich S; Piergies AA
Antiviral Res; 1997 Jun; 35(1):53-63. PubMed ID: 9224961
[TBL] [Abstract][Full Text] [Related]
10. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
Moyle G
Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
[TBL] [Abstract][Full Text] [Related]
11. Delavirdine/protease inhibitor interactions.
Gilden D
GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839
[TBL] [Abstract][Full Text] [Related]
12. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry M; Gibbons S; Back D; Mulcahy F
Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Clin Pharmacokinet; 2011 Jan; 50(1):25-39. PubMed ID: 21142266
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of antiretrovirals in pregnant women.
Mirochnick M; Capparelli E
Clin Pharmacokinet; 2004; 43(15):1071-87. PubMed ID: 15568888
[TBL] [Abstract][Full Text] [Related]
16. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
[TBL] [Abstract][Full Text] [Related]
17. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.
Fichtenbaum CJ; Gerber JG
Clin Pharmacokinet; 2002; 41(14):1195-211. PubMed ID: 12405866
[TBL] [Abstract][Full Text] [Related]
18. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of action and pharmacokinetics of rilpivirine].
Portilla J; Estrada V
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]